ADCETRIS^® Combination Significantly Improves Overall Survival in Newly Diagnosed Patients with Advanced Hodgkin Lymphoma

Seagen, Inc. announced that the Phase III ECHELON-1 clinical trial demonstrated a statistically significant improvement in overall survival in patients with advanced classical Hodgkin lymphoma following treatment with ADCETRIS in combination with chemotherapy.